Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gracell Biotechnologies Inc. Gracell Biotechnologies Acquisition Completed February 22, 2024 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement February 20, 2024 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma January 29, 2024 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases December 26, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus December 21, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 December 11, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus November 27, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit November 16, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update November 13, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program November 08, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition November 02, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences November 01, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting October 31, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023 October 30, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate September 27, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma September 26, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders September 19, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences September 14, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences August 24, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update August 14, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023 July 31, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference July 31, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium June 20, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate June 10, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in Jefferies Healthcare Conference May 24, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd May 15, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update May 15, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences May 10, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023 May 02, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 April 25, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Tickers GRCL Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.